These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 21786575

  • 1. [Left ventricular hypertrophy in end-stage renal disease and its possible regression as a result of correction of anemia and arterial hypertension].
    Dzgoeva FU, Gatagonova TM, Kadzaeva ZK, Khamitsaeva OV, Kochisova ZKh, Dzutseva AT, Bazaeva BG.
    Ter Arkh; 2011; 83(6):42-6. PubMed ID: 21786575
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Treatment of renal anemia by erythropoietin substitution. The effects on the cardiovascular system.
    Radermacher J, Koch KM.
    Clin Nephrol; 1995 Nov; 44 Suppl 1():S56-60. PubMed ID: 8608665
    [Abstract] [Full Text] [Related]

  • 5. Effects of optimized heart failure therapy and anemia correction with epoetin beta on left ventricular mass in hemodialysis patients.
    Hampl H, Hennig L, Rosenberger C, Amirkhalily M, Gogoll L, Riedel E, Scherhag A.
    Am J Nephrol; 2005 Nov; 25(3):211-20. PubMed ID: 15900093
    [Abstract] [Full Text] [Related]

  • 6. Cardiac mortality prevention in uremic patients. Therapeutic strategies with particular attention to complete correction of renal anemia.
    Berweck S, Hennig L, Sternberg C, Dingerkus H, Ludat K, Hampl H.
    Clin Nephrol; 2000 Feb; 53(1 Suppl):S80-5. PubMed ID: 10746811
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Cardioprotective effect of erythropoietin preparations in patients with chronic renal failure].
    Nikolaev AIu, Ermolenko VM, Milovanova LIu, Milovanov IuS.
    Ter Arkh; 2004 Feb; 76(9):40-3. PubMed ID: 15532375
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Diastolic dysfunction in different types of left ventricular hypertrophy in patients with end-stage renal failure: impact of long-term erythropoietin therapy].
    Dzgoeva FU, Gatagonova TM, Kadzaeva ZK, Khamitsaeva OV, Kochisova ZKh, Dzueva AT, Bazaeva BG, Bestaeva TL.
    Ter Arkh; 2013 Feb; 85(6):44-50. PubMed ID: 23866598
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Dihydropyridines versus other agents in the treatment of hypertension in the elderly. Part 1: Antihypertensive therapy and left ventricular hypertrophy.
    Fagard R, Staessen J, Thijs L, Van Hoof R, Amery A.
    J Hypertens Suppl; 1993 Dec; 11(6):S27-9. PubMed ID: 7909547
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Arterial hypertension and left ventricular hypertrophy in hemodialysis patients.
    Paoletti E, Cannella G.
    Clin Nephrol; 2002 Jul; 58 Suppl 1():S46-51. PubMed ID: 12227726
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.